[Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation]

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• The T790M mutation in the epidermal growth factor receptor (EGFR) gene is a key mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs).
• While secondary T790M mutations are clinically emphasized, de novo T790M mutations, present at diagnosis, are often neglected.
• Advancements in sequencing technology have increased the detection rate of de novo T790M mutations.

Purpose of the Study:

• To review the incidence, characteristics, and clinical implications of de novo T790M mutations.
• To highlight the differences between de novo and secondary T790M mutations.
• To assess the impact of de novo T790M mutations on treatment strategies and outcomes.

Main Methods:

• Systematic literature review of studies reporting de novo T790M mutations.
• Analysis of factors influencing the detection rate of de novo T790M mutations, including sequencing techniques.
• Evaluation of the clinical significance and prognostic value of de novo T790M mutations.

Main Results:

• The incidence of de novo T790M mutations varies significantly, primarily influenced by the sensitivity of sequencing techniques.
• De novo T790M mutations are often characterized by low allelic abundance and co-occurrence with other genetic alterations.
• These mutations appear to be a poor predictor and prognostic factor, with limited efficacy of first and second-generation EGFR-TKIs.

Conclusions:

• De novo T790M mutations represent a distinct clinical entity requiring further investigation.
• The therapeutic value of third-generation EGFR-TKIs, such as osimertinib, in the context of de novo T790M mutations warrants dedicated study.
• Clinical guidelines should consider the implications of de novo T790M mutations in treatment decisions.